Back HCV Treatment Treatment Guidelines

HCV Treatment Guidelines

9. Evolving Hepatitis C Therapy Guidelines and Treatment Cascade

The first U.S. hepatitis C treatment guidelines incorporating interferon-free direct-acting antiviral regimens were issued in January 2014 and periodically updated to reflect new drug approvals and emerging data from studies and real-world use. The new therapies have cure rates above 90%, but cost and other barriers have limited their use.

alt

Read more:

Updated Hepatitis C Treatment Guidelines Add New Therapies, Hard-to-Treat Patients

The American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA), and International Antiviral Society-USA (IAS-USA) recently updated their hepatitis C treatment guidelines to add newly approved interferon-free direct-acting antiviral regimens and to provide more information about treating patients with HIV/HCV coinfection and decompensated liver disease. The evolving guidelines are available online at HCVguidelines.org.

alt

Read more:

EASL 2014: European Liver Specialists Recommend Use of Newest Hepatitis C Drugs

The European Association for the Study of the Liver (EASL) has issued new guidelines for the treatment of hepatitis C, which recommend that wherever possible, patients should be treated with the newest direct-acting antivirals. The guidelines also recommend physicians should "mix and match" antivirals from different companies to get the most potent regimens.

alt

Read more:

New Hepatitis C Guidelines: Who Should Be Treated and When?

Everyone with chronic hepatitis C could potentially benefit from treatment with new direct-acting antivirals, but when resources are limited, people with advanced liver disease, those at greatest risk for complications, and those most likely to transmit HCV should be treated most urgently, according to new guidelines released this week from AASLD, IDSA, and IAS-USA.

alt

Read more:

EASL 2014: WHO Recommends Global Use of Newest Hepatitis C Drugs, Urges Price Reductions

The World Health Organization has issued global treatment guidelines for hepatitis C, strongly recommending the use of the new direct-acting antivirals sofosbuvir (Sovaldi) with ribavirin for HCV genotypes 1, 2, 3, and 4, or simeprevir (Olysio) with pegylated interferon interferon and ribavirin for genotype 1 infection. The WHO guidelines were released to coincide with the 49th International Liver Congress this week in London. New guidelines from the European Association for the Study of the Liver (EASL) will be released on Saturday.

alt

Read more: